At present, PTH, PTHrP, and sclerostin antibodies for the treatment of osteoporosis are all protein drugs that have defects such as immunogenicity, easy degradation, high price, short half-life, and poor permeability (Vargason et al., 2021). This evidence concerns the gene PTHLH and osteoporosis.